Drug intelligence / Profile preview

BAN3014

Development stage: Preclinical
Lead developer: BioArctic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

BAN3014 is a monoclonal antibody drug candidate being developed by BioArctic AB in collaboration with Eisai. It is designed to target toxic aggregated forms of the TAR DNA-binding protein 43 (TDP-43), specifically oligomers and protofibrils, which are implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). By selectively binding to these misfolded protein species, BAN3014 aims to reduce their neurotoxic effects and slow disease progression. The drug is currently in the preclinical/IND-enabling stage, following the nomination of a drug candidate for clinical development.

Other names: BAN3014 (TDP-43)

Targets

TARDBP (TAR DNA-binding protein 43)

Beyond the preview

Go deeper on BAN3014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAN3014.

Explore the full profile